Craig- the comment about not being treated fairly
Post# of 148110
We know the P3 combo trial hit the PE, which makes it different from CD12. Did the FDA issue the RTF due to lack of required data, or are they just flexing on us? It is quite possible that CYDY didn't have everything buttoned up in a pretty little package, but a never ending string of experts like Mahboob to take us over the line seems to get us nowhere. Do we have the data the FDA requires or not? If we do, we'll be fine in a year. If not...well...let's just say another trial would be a problem.
No reason to sell below $2, even for the longs who bought at 50 cent averages unless you believe we can't overcome the BLA hurdle.